Early Detection Research Network

Targeting p53-dependent stem cell loss for intestinal chemoprotection.

The gastrointestinal (GI) epithelium is the fastest renewing adult tissue and is maintained by tissue-specific stem cells. Treatment-induced GI side effects are a major dose-limiting factor for chemotherapy and abdominal radiotherapy and can decrease the quality of life in cancer patients and survivors. p53 is a key regulator of the DNA damage response, and its activation results in stimulus- and cell type-specific outcomes via distinct effectors. We demonstrate that p53-dependent PUMA induction mediates chemotherapy-induced intestinal injury in mice. Genetic ablation of <i>Puma</i>, but not of <i>p53</i>, protects against chemotherapy-induced lethal GI injury. Blocking chemotherapy-induced loss of LGR5<sup>+</sup> stem cells by <i>Puma</i> KO or a small-molecule PUMA inhibitor (PUMAi) prevents perturbation of the stem cell niche, rapid activation of WNT and NOTCH signaling, and stem cell exhaustion during repeated exposures. PUMAi also protects human and mouse colonic organoids against chemotherapy-induced apoptosis and damage but does not protect cancer cells in vitro or in vivo. Therefore, targeting PUMA is a promising strategy for normal intestinal chemoprotection because it selectively blocks p53-dependent stem cell loss but leaves p53-dependent protective effects intact.

Beumer JH, Buchanan ME, Eiseman JL, Leibowitz BJ, Parise RA, Rachid M, Schoen RE, Wei L, Yang L, Yu J, Zhang L


Sci Transl Med, 2018, 10 (427)

Version 5.0.2